WO2002085375A8 - Nouvelle composition hormonale et son utilisation - Google Patents

Nouvelle composition hormonale et son utilisation

Info

Publication number
WO2002085375A8
WO2002085375A8 PCT/FR2002/001384 FR0201384W WO02085375A8 WO 2002085375 A8 WO2002085375 A8 WO 2002085375A8 FR 0201384 W FR0201384 W FR 0201384W WO 02085375 A8 WO02085375 A8 WO 02085375A8
Authority
WO
WIPO (PCT)
Prior art keywords
gestagenic
estro
relates
estrogenic
component
Prior art date
Application number
PCT/FR2002/001384
Other languages
English (en)
Other versions
WO2002085375A1 (fr
Inventor
Jacques Paris
Jean-Louis Thomas
Original Assignee
Theramex
Jacques Paris
Jean-Louis Thomas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theramex, Jacques Paris, Jean-Louis Thomas filed Critical Theramex
Priority to BR0205104-4A priority Critical patent/BR0205104A/pt
Priority to AU2002310721A priority patent/AU2002310721A1/en
Publication of WO2002085375A1 publication Critical patent/WO2002085375A1/fr
Priority to NO20026215A priority patent/NO20026215L/no
Publication of WO2002085375A8 publication Critical patent/WO2002085375A8/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention se rapporte au domaine de la chimie thérapeutique et plus particulièrement au domaine de la technique pharmaceutique hormonale, Elle a plus précisément pour objet de nouvelles compositions pharmaceutiques hormonales formées d'une association estroprogestative constituée d'un composé estrogène et d'un composé progestatif, en association ou en mélange avec un ou plusieurs excipients non toxiques, inertes, pharmaceutiquement acceptables, destinées a l'administration par voie orale. La présente invention concerne aussi l'utilisation du mélange estroprogestatif dans lequel le composant estrogénique et le composant progestatif sont administrés de façon combinée. L'association combinée peut être prescrite de façon continue ou intermittente, en vue de la réalisation d'une composition destinée à traiter les carences estrogéniques, à prévenir L'ostéoporose et les maladies cardio-vasculaires chez la femme ménopausée. L'invention a encore pour objet un procédé de préparation de ces nouvelles compositions pharmaceutiques estroprogestatives.
PCT/FR2002/001384 2001-04-25 2002-04-23 Nouvelle composition hormonale et son utilisation WO2002085375A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
BR0205104-4A BR0205104A (pt) 2001-04-25 2002-04-23 Composição hormonal inédita e sua utilização
AU2002310721A AU2002310721A1 (en) 2001-04-25 2002-04-23 Novel hormone composition
NO20026215A NO20026215L (no) 2001-04-25 2002-12-23 Nytt hormonpreparat

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0105557A FR2823976A1 (fr) 2001-04-25 2001-04-25 Nouvelle composition hormonale et son utilisation
FR01/05557 2001-04-25

Publications (2)

Publication Number Publication Date
WO2002085375A1 WO2002085375A1 (fr) 2002-10-31
WO2002085375A8 true WO2002085375A8 (fr) 2003-02-20

Family

ID=8862668

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2002/001384 WO2002085375A1 (fr) 2001-04-25 2002-04-23 Nouvelle composition hormonale et son utilisation

Country Status (9)

Country Link
KR (1) KR20030043797A (fr)
CN (1) CN1464787A (fr)
AR (1) AR033260A1 (fr)
AU (1) AU2002310721A1 (fr)
BR (1) BR0205104A (fr)
FR (1) FR2823976A1 (fr)
MA (1) MA26833A1 (fr)
NO (1) NO20026215L (fr)
WO (1) WO2002085375A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8022053B2 (en) 2004-11-02 2011-09-20 Bayer Schering Pharma Aktiengesellschaft Oral solid dosage forms containing a low dose of estradiol
GT200500315A (es) * 2004-11-02 2006-06-06 Formas de dosificacion oral solidas que contienen una dosis baja de estradiol

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826831A (en) * 1983-08-05 1989-05-02 Pre Jay Holdings Limited Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens
US5208225A (en) * 1986-02-27 1993-05-04 Warner-Lambert Company Compositions containing fixed combinations
FR2754179B1 (fr) * 1996-10-08 1998-12-24 Theramex Nouvelle composition hormononale et son utilisation

Also Published As

Publication number Publication date
KR20030043797A (ko) 2003-06-02
CN1464787A (zh) 2003-12-31
NO20026215L (no) 2003-02-21
BR0205104A (pt) 2003-05-20
NO20026215D0 (no) 2002-12-23
AR033260A1 (es) 2003-12-10
WO2002085375A1 (fr) 2002-10-31
MA26833A1 (fr) 2004-12-20
AU2002310721A1 (en) 2002-11-05
FR2823976A1 (fr) 2002-10-31

Similar Documents

Publication Publication Date Title
WO2001070208A3 (fr) Therapie par remplacement d'hormones
WO2002022132A8 (fr) Nouvelles compositions estro-progestatives topiques a effet systemique
WO2006023496A3 (fr) Compositions de creme vaginale, kits correspondants et procedes d'utilisation
WO2002074292A3 (fr) Therapie de remplacement d'hormones
WO2006135638A3 (fr) Compositions de tanaproget comprenant de l'estradiol d'ethinyle
HK1106717A1 (en) Microparticles consisting of estradiol and cholesterol
CA2505128A1 (fr) Procedes et compositions utilisant des composes immunomodulateurs pour traiter et maitriser des cancers et d'autres maladies
HK1047248A1 (en) Pharmaceutical combination of micronised drospirenone and an estrogen for hormone replacement therapy.
WO2004016244A3 (fr) Compositions pharmaceutiques pour l'administration buccale de medicaments analgesiques
AP1625A (en) Hormonal composition based on a progesterone and an oestrogen and use thereof.
GB2395434A (en) Composition for reducing appetite in mammals comprising proxyanidin
YU18099A (sh) Hormonalni preparat koji sadrži jedinjenje estrogena i progestativno jedinjenje
CA2467676A1 (fr) Utilisation de glutamate, de metabolites ou de derives du glutamate, d'analogues du glutamate ou de melanges de ceux-ci pour preparer une composition destinee au traitement de l'osteoporose
WO2003005967A3 (fr) Formulation a liberation double comportant un ester ethylique de levodopa et un inhibiteur de decarboxylase dans une couche a liberation instantanee avec un ester ethylique de levodopa et un inhibiteur de decarboxylase dans un noyau a liberation controlee
IL159714A (en) Pharmaceutical composition for oral delivery comprising a fragment of parathyroid hormone and 5-cnac
SG154323A1 (en) Estrogen replacement therapy
WO2004016243A3 (fr) Methodes d'administration et d'amelioration de l'absorption d'agents pharmaceutiques
WO2002085375A8 (fr) Nouvelle composition hormonale et son utilisation
HK1060850A1 (en) Pharmaceutical composition for treatment of phimosis using topical corticosteroid
CR6627A (es) Nuevo medicamento contraceptivo y su modo de preparacion
WO2003084521A3 (fr) Traitement hormonal substitutif
WO2000067708A3 (fr) Compositions d'hormones steroides a administration orale et methodes d'utilisation
EP1857110A3 (fr) Thérapie de substitution hormonale
WO2003045971A3 (fr) Medicament
WO2003045398A8 (fr) Procedes de fabrication de formulations pharmaceutiques comprenant du 7alpha, 11beta-dimethy-17beta-hydroxyestra-4, 14-dien-3-one et des esters en position 17 de ce compose

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AU BA BG BR CA CN CO CR CU CZ DZ EC EE HR HU ID IL IN IS JP KR LT LV MA MK MX NO NZ PH PL RO SG SI TN US VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 200210387

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 1020027017624

Country of ref document: KR

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: C1

Designated state(s): AE AL AU BA BG BR CA CN CO CR CU CZ DZ EC EE HR HU ID IL IN IS JP KR LT LV MA MK MX NO NZ PH PL RO SG SI TN US VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i
WWE Wipo information: entry into national phase

Ref document number: 028022122

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 1020027017624

Country of ref document: KR

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP